Aaron S Kesselheim

发表

Aaron S Kesselheim, Jerry Avorn, 2013, BMJ.

Metrics for quantifying antibiotic use in the hospital setting: results from a systematic review and international multidisciplinary consensus procedure

Arjun Srinivasan, John H Rex, Claudia Wild, 2018, The Journal of antimicrobial chemotherapy.

Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.

Jessica M Franklin, Aaron S Kesselheim, Jerry Avorn, 2016, JAMA internal medicine.

Experience With the Priority Review Voucher Program for Drug Development.

Aaron S Kesselheim, A. Kesselheim, A. Sarpatwari, 2015, JAMA.

Trends in Pricing and Generic Competition Within the Oral Antibiotic Drug Market in the United States

Aaron S Kesselheim, Lei Zhang, A. Kesselheim, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The variability and quality of medication container labels.

William H Shrank, Aaron S Kesselheim, Jerry Avorn, 2007, Archives of internal medicine.

Why do the same drugs look different? Pills, trade dress, and public health.

Aaron S Kesselheim, A. Kesselheim, J. Greene, 2011, The New England journal of medicine.

Rethinking global access to vaccines

Aaron S Kesselheim, A. Kesselheim, D. Chokshi, 2008, BMJ : British Medical Journal.

The role of litigation in defining drug risks.

Aaron S Kesselheim, Jerry Avorn, A. Kesselheim, 2007, JAMA.

Regulation of medical devices in the United States and European Union.

Aaron S Kesselheim, A. Kesselheim, D. Kramer, 2012, The New England journal of medicine.

A randomized study of how physicians interpret research funding disclosures.

Steven Joffe, Robert J Glynn, Aaron S Kesselheim, 2012, The New England journal of medicine.

Generating comparative evidence on new drugs and devices before approval

Andrea Cipriani, Georgia Salanti, Huseyin Naci, 2020, The Lancet.

Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results.

Bo Wang, Daniel Carpenter, Jessica M Franklin, 2016, JAMA internal medicine.

Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.

Aaron S Kesselheim, A. Kesselheim, M. Mello, 2007, Health affairs.

Meta-analyses involving cross-over trials: methodological issues.

M Alan Brookhart, Aaron S Kesselheim, François Curtin, 2011, International journal of epidemiology.

Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals.

Kevin Outterson, Aaron S Kesselheim, A. Kesselheim, 2010, Health affairs.

Progress and Hurdles for Follow-on Biologics.

Aaron S Kesselheim, Jerry Avorn, A. Kesselheim, 2015, The New England journal of medicine.

Innovative research methods for studying treatments for rare diseases: methodological review

Joshua J Gagne, Aaron S Kesselheim, Lauren Thompson, 2014, BMJ : British Medical Journal.

Quality indicators for responsible antibiotic use in the inpatient setting: a systematic review followed by an international multidisciplinary consensus procedure

Arjun Srinivasan, John H Rex, Claudia Wild, 2018, The Journal of antimicrobial chemotherapy.

The roles of academia, rare diseases, and repurposing in the development of the most transformative drugs.

Aaron S Kesselheim, Jerry Avorn, A. Kesselheim, 2015, Health affairs.

Overbilling vs. downcoding--the battle between physicians and insurers.

Aaron S Kesselheim, T. Brennan, A. Kesselheim, 2005, The New England journal of medicine.

False Negative Tests for SARS-CoV-2 Infection - Challenges and Implications.

Steven Woloshin, Aaron S Kesselheim, A. Kesselheim, 2020, The New England journal of medicine.

Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.

Aaron S Kesselheim, Jerry Avorn, A. Kesselheim, 2011, JAMA.

Lifecycle Regulation of Artificial Intelligence- and Machine Learning-Based Software Devices in Medicine.

Aaron S Kesselheim, A. Kesselheim, T. Hwang, 2019, JAMA.

Variations in pill appearance of antiepileptic drugs and the risk of nonadherence.

William H Shrank, Aaron S Kesselheim, Jerry Avorn, 2013, JAMA internal medicine.

Use of Health Care Databases to Support Supplemental Indications of Approved Medications

Sebastian Schneeweiss, Aaron S Kesselheim, Jerry Avorn, 2018, JAMA internal medicine.

Regulating incremental innovation in medical devices

Aaron S Kesselheim, A. Kesselheim, P. V. Rajan, 2014, BMJ : British Medical Journal.

FDA regulation of mobile health technologies.

Aaron S Kesselheim, I Glenn Cohen, A. Kesselheim, 2014, The New England journal of medicine.

Burden of Changes in Pill Appearance for Patients Receiving Generic Cardiovascular Medications After Myocardial Infarction

Aaron S Kesselheim, Jerry Avorn, Katsiaryna Bykov, 2014, Annals of Internal Medicine.

Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.

M Alan Brookhart, William H Shrank, Aaron S Kesselheim, 2008, JAMA.

New FDA breakthrough-drug category--implications for patients.

Jonathan J. Darrow, Aaron S Kesselheim, Jerry Avorn, 2014, The New England journal of medicine.

Electronic medication packaging devices and medication adherence: a systematic review.

Aaron S Kesselheim, Jerry Avorn, Krista F Huybrechts, 2014, JAMA.

Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study.

Joshua J Gagne, Aaron S Kesselheim, Jerry Avorn, 2017, European journal of cancer.

Will physician-level measures of clinical performance be used in medical malpractice litigation?

Aaron S Kesselheim, David M Studdert, A. Kesselheim, 2006, JAMA.